Published in Antimicrob Agents Chemother on February 01, 1990
Zygomycetes in human disease. Clin Microbiol Rev (2000) 9.80
New and emerging yeast pathogens. Clin Microbiol Rev (1995) 4.75
Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03
Drs2p-related P-type ATPases Dnf1p and Dnf2p are required for phospholipid translocation across the yeast plasma membrane and serve a role in endocytosis. Mol Biol Cell (2003) 2.65
Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother (2005) 2.35
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol (2013) 1.88
Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev (1996) 1.85
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother (1993) 1.83
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Universal behavior of membranes with sterols. Biophys J (2005) 1.57
Molecular dynamics simulation of the structure of dimyristoylphosphatidylcholine bilayers with cholesterol, ergosterol, and lanosterol. Biophys J (2001) 1.55
Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother (1994) 1.53
Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother (2011) 1.45
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother (1991) 1.39
Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants. Antimicrob Agents Chemother (1998) 1.29
Current concepts in antifungal pharmacology. Mayo Clin Proc (2011) 1.26
Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob Agents Chemother (1995) 1.24
Functional consequences of oxidative membrane damage. J Membr Biol (2005) 1.23
A post-PKS oxidation of the amphotericin B skeleton predicted to be critical for channel formation is not required for potent antifungal activity. J Am Chem Soc (2007) 1.22
In vitro antifungal and fungicidal activities and erythrocyte toxicities of cyclic lipodepsinonapeptides produced by Pseudomonas syringae pv. syringae. Antimicrob Agents Chemother (1996) 1.17
Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother (2000) 1.16
Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob Agents Chemother (1999) 1.15
Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site. Antimicrob Agents Chemother (2002) 1.13
Synthesis-enabled functional group deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities. Proc Natl Acad Sci U S A (2011) 1.11
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Front Microbiol (2012) 1.11
Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ (1992) 1.10
Virulence of a phosphoribosylaminoimidazole carboxylase-deficient Candida albicans strain in an immunosuppressed murine model of systemic candidiasis. Infect Immun (2001) 1.06
Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory. J Clin Microbiol (1995) 1.05
Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes. Antimicrob Agents Chemother (2004) 1.04
The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrob Agents Chemother (1994) 1.04
Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis (2004) 1.02
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother (2002) 1.01
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother (1999) 1.01
Determination of antifungal susceptibility patterns among the clinical isolates of Candida species. J Glob Infect Dis (2011) 1.01
Physicochemical cell damage in relation to lethal amphotericin B action. Antimicrob Agents Chemother (1994) 1.00
Molecular aspects of the interaction between amphotericin B and a phospholipid bilayer: molecular dynamics studies. J Mol Model (2004) 0.98
Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro. Antimicrob Agents Chemother (1992) 0.97
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother (2003) 0.97
Neurotrophic natural products: chemistry and biology. Angew Chem Int Ed Engl (2013) 0.96
Amphotericin B channels in the bacterial membrane: role of sterol and temperature. Biophys J (2003) 0.96
Structure of cytochrome P450 PimD suggests epoxidation of the polyene macrolide pimaricin occurs via a hydroperoxoferric intermediate. Chem Biol (2010) 0.95
Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother (1997) 0.94
Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments. Eur Biophys J (2014) 0.91
Synergism between the antifungal agents amphotericin B and alkyl glycerol ethers. Antimicrob Agents Chemother (1994) 0.90
Modification of rapid susceptibility assay for antifungal susceptibility testing of Aspergillus fumigatus. J Clin Microbiol (2003) 0.89
Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis. Antimicrob Agents Chemother (2014) 0.88
Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob Agents Chemother (2001) 0.87
Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles. Antimicrob Agents Chemother (1990) 0.87
Candida infections and their prevention. ISRN Prev Med (2012) 0.86
Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasion. PLoS One (2010) 0.85
NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning. PLoS Comput Biol (2016) 0.85
Self-aggregated nanoparticles based on amphiphilic poly(lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B. Int J Nanomedicine (2013) 0.84
Antifungals: need to search for a new molecular target. Indian J Pharm Sci (2010) 0.84
Apoptotic-like programed cell death in fungi: the benefits in filamentous species. Front Oncol (2012) 0.83
Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture. J Virol (2011) 0.83
Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations. Antimicrob Agents Chemother (1992) 0.83
Amphotericin B protects cis-parinaric acid against peroxyl radical-induced oxidation: amphotericin B as an antioxidant. Antimicrob Agents Chemother (1997) 0.83
Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone). Antimicrob Agents Chemother (1992) 0.83
Human phagocytic cell responses to Scedosporium apiospermum (Pseudallescheria boydii): variable susceptibility to oxidative injury. Infect Immun (2003) 0.82
Identification of yeast genes that confer resistance to chitosan oligosaccharide (COS) using chemogenomics. BMC Genomics (2012) 0.81
KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis. Antimicrob Agents Chemother (1998) 0.81
Sterol and fatty acid composition of Candida lusitaniae clinical isolates. Antimicrob Agents Chemother (2002) 0.81
Formulation and evaluation of microemulsion based delivery system for amphotericin B. AAPS PharmSciTech (2008) 0.81
Effect of ketoconazole on lethal action of amphotericin B on Leishmania mexicana promastigotes. Antimicrob Agents Chemother (1994) 0.80
The effect of antifungal combination on transcripts of a subset of drug-resistance genes in clinical isolates of Candida species induced biofilms. Saudi Pharm J (2013) 0.80
Amphotericin B resistance and membrane fluidity in Kluyveromyces lactis strains. Antimicrob Agents Chemother (2000) 0.80
Ion coordination in the amphotericin B channel. Biophys J (1996) 0.79
Nanodisks protect amphotericin B from ultraviolet light and oxidation-induced damage. Pest Manag Sci (2009) 0.78
Inactivation by ionizing radiation of ion channels formed by polyene antibiotics amphotericin B and nystatin in lipid membranes: an inverse dose-rate behavior. Biophys J (1993) 0.78
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs (2014) 0.77
Fungal lethality, binding, and cytotoxicity of syringomycin-E. Antimicrob Agents Chemother (1999) 0.77
Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection. Antimicrob Agents Chemother (2005) 0.77
Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells. Br J Cancer (1994) 0.77
In vitro analyses of mild heat stress in combination with antifungal agents against Aspergillus fumigatus biofilm. Antimicrob Agents Chemother (2013) 0.76
Cell Wall Changes in Amphotericin B-Resistant Strains from Candida tropicalis and Relationship with the Immune Responses Elicited by the Host. Antimicrob Agents Chemother (2016) 0.76
The Role of Signaling via Aqueous Pore Formation in Resistance Responses to Amphotericin B. Antimicrob Agents Chemother (2016) 0.76
Conformational properties of amphotericin B amide derivatives--impact on selective toxicity. J Comput Aided Mol Des (2000) 0.76
pH regulation of amphotericin B channels activity in the bilayer lipid membrane. J Nat Sci Biol Med (2016) 0.75
Deciphering the interplay between cysteine synthase and thiol cascade proteins in modulating Amphotericin B resistance and survival of Leishmania donovani under oxidative stress. Redox Biol (2017) 0.75
The Mechanistic Targets of Antifungal Agents: An Overview. Mini Rev Med Chem (2016) 0.75
Mixture-based heterocyclic combinatorial positional scanning libraries: discovery of bicyclic guanidines having potent antifungal activities against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother (1999) 0.75
New challenges to the therapy of systemic fungal infections. Trans Am Clin Climatol Assoc (1996) 0.75
Effect of amphotericin B nanodisks on plant fungal diseases. Pest Manag Sci (2011) 0.75
Quinacrine inhibits Candida albicans growth and filamentation at neutral pH. Antimicrob Agents Chemother (2014) 0.75
Amphotericin B induces glial cell line-derived neurotrophic factor in the rat brain. J Vet Med Sci (2014) 0.75
David and Goliath: chemical perturbation of eukaryotes by bacteria. J Ind Microbiol Biotechnol (2015) 0.75
Probable Mechanism(s) of Antifungal Activity of SJA-95, a Heptaene Polyene Antibiotic. Indian J Pharm Sci (2010) 0.75
Effect of fasting on temporal variation in the nephrotoxicity of amphotericin B in rats. Antimicrob Agents Chemother (1999) 0.75
Nanostructured delivery systems with improved leishmanicidal activity: a critical review. Int J Nanomedicine (2017) 0.75
Amphotericin B potentiates the anticancer activity of doxorubicin on the MCF-7 breast cancer cells. J Chem Biol (2017) 0.75
Alkyl Protocatechuate-Loaded Nanostructured Lipid Systems as a Treatment Strategy for Paracoccidioides brasiliensis and Paracoccidioides lutzii In Vitro. Front Microbiol (2017) 0.75
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother (1988) 4.79
Antifungal susceptibility tests. Antimicrob Agents Chemother (1987) 4.76
Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother (1980) 4.53
How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta (1986) 4.22
Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A (1972) 4.09
Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother (1979) 3.79
The development of resistance by candida species to polyene antibiotics in vitro. J Med Microbiol (1971) 2.79
Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med (1988) 2.44
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis (1986) 2.08
Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol (1979) 2.03
Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci (1979) 2.02
Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies. Am J Med (1976) 1.93
Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med (1985) 1.84
Lipid composition and polyene antibiotic resistance of Candida albicans mutants. Can J Biochem (1978) 1.82
Catheter-associated fungemia caused by Fusarium chlamydosporum in a patient with lymphocytic lymphoma. J Clin Microbiol (1985) 1.79
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Classification of polyene antibiotics according to chemical structure and biological effects. Antimicrob Agents Chemother (1979) 1.69
Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother (1985) 1.62
Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis (1982) 1.49
The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. J Med Vet Mycol (1987) 1.49
Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study. Biochemistry (1983) 1.48
Comparative in vitro antifungal activity of amphotericin B and amphotericin B methyl ester. Antimicrob Agents Chemother (1975) 1.36
Comparative chemotherapeutic activity of amphotericin B and amphotericine B methy ester. Antimicrob Agents Chemother (1975) 1.35
DEVELOPMENT OF RESISTANCE TO POLYENE ANTIBIOTICS IN CANDIDA ALBICANS. J Bacteriol (1965) 1.35
Quantitative structure-activity relationships in amphotericin B derivatives. Biochem Pharmacol (1988) 1.27
Sterols from polyene-resistant mutants of Candida albicans. J Gen Microbiol (1972) 1.25
Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother (1988) 1.11
Mechanism of inactivation of the polyene antibiotic amphotericin B. Evidence for radical formation in the process of autooxidation. J Antibiot (Tokyo) (1985) 1.10
Application of differential spectra in the ultraviolet-visible region to study the formation of amphotericin B-sterol complexes. Biochim Biophys Acta (1980) 1.08
Effect of the polar head structure of polyene macrolide antifungal antibiotics on the mode of permeabilization of ergosterol- and cholesterol-containing lipidic vesicles studied by 31P-NMR. Mol Pharmacol (1986) 1.06
Nature and development of phenotypic resistance to amphotericin B in Candida albicans. Adv Microb Physiol (1986) 1.05
Interaction of the polyene antibiotic amphotericin B with model membranes: differences between small and large unilamellar vesicles. Biochimie (1989) 1.01
Haemolytic activity of aromatic heptaenes. A group of polyene macrolide antifungal antibiotics. Biochem Pharmacol (1984) 1.01
Comparative conformational analysis of cholesterol and ergosterol by molecular mechanics. Eur Biophys J (1989) 1.00
Polyene toxicity in renal medulla: injury mediated by transport activity. Science (1984) 0.98
Stimulatory, permeabilizing, and toxic effects of amphotericin B on L cells. Antimicrob Agents Chemother (1984) 0.98
In vitro activity of systemic antifungal agents against Malassezia furfur. Antimicrob Agents Chemother (1987) 0.98
Interaction of amphotericin B and its N-fructosyl derivative with murine thymocytes: a comparative study using fluorescent membrane probes. Biochim Biophys Acta (1989) 0.96
Toxicity and induction of resistance to Listeria monocytogenes infection by amphotericin B in inbred strains of mice. Infect Immun (1986) 0.95
Two mechanisms of synergism when amphotericin B is used in combination with actinomycin D or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea against the human promyelocytic leukemia cell line HL-60. Cancer Res (1986) 0.91
Effects of ascorbic acid on the antifungal action of amphotericin B. J Antimicrob Chemother (1989) 0.88
Sensitivity of Candida albicans to amphotericin B administered as single or fractionated doses. Antimicrob Agents Chemother (1986) 0.87
Interaction of 14C-labelled amphotericin B derivatives with human erythrocytes: relationship between binding and induced K+ leak. Biochim Biophys Acta (1988) 0.87
Parallel inheritance of tissue catalase activity and immunostimulatory action of amphotericin B in inbred mouse strains. Cell Immunol (1987) 0.86
Eburicol, lichesterol, ergosterol, and obtusifoliol from polyene antibiotic-resistant mutants of Candida albicans. Can J Microbiol (1977) 0.85
Spin-labeled amphotericin B: synthesis, characterization, biological and spectroscopic properties. Biochim Biophys Acta (1987) 0.84
B cell triggering properties of a nontoxic derivative of amphotericin B. J Immunol (1986) 0.84
Treatment of fungal infections with semisynthetic derivatives of amphotericin B alpha. Ann N Y Acad Sci (1988) 0.82
Comparative in vitro and in vivo evaluation of N-D-ornithyl amphotericin B methyl ester, amphotericin B methyl ester, and amphotericin B. Antimicrob Agents Chemother (1987) 0.80
Interaction of the polyene antibiotic etruscomycin with large unilamellar lipid vesicles: binding and proton permeability inducement. Biochim Biophys Acta (1985) 0.79
Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin. Antimicrob Agents Chemother (1976) 6.26
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis (1992) 4.98
Classification of Histoplasma capsulatum isolates by restriction fragment polymorphisms. J Bacteriol (1986) 4.55
Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A (1972) 4.09
Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med (1971) 4.02
Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med (1970) 3.74
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole. Antimicrob Agents Chemother (1978) 3.29
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Strategies in the treatment of systemic fungal infections. N Engl J Med (1980) 2.89
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Evaluation of rooms with negative pressure ventilation used for respiratory isolation in seven midwestern hospitals. Infect Control Hosp Epidemiol (1993) 2.65
Antimicrobial misuse in patients with positive blood cultures. Am J Med (1989) 2.45
Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med (1988) 2.44
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science (1972) 2.31
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
New fluorescence assay for the quantitation of fungi. J Clin Microbiol (1989) 2.26
Potentiation of the antifungal effects of antibiotics by amphotericin B. Antimicrob Agents Chemother (1972) 2.24
Rapid radiometric method of testing susceptibility of mycobacteria and slow-growing fungi to antimicrobial agents. Antimicrob Agents Chemother (1974) 2.22
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol (1983) 2.11
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae. Antimicrob Agents Chemother (1979) 2.09
Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis (1986) 2.08
Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med (1970) 2.05
Typing of Histoplasma capsulatum by restriction fragment length polymorphisms in a nuclear gene. J Clin Microbiol (1992) 2.02
Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis (1984) 1.93
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Use of mitochondrial and ribosomal DNA polymorphisms to classify clinical and soil isolates of Histoplasma capsulatum. Infect Immun (1989) 1.85
Comparison of the separation of Candida albicans chromosome-sized DNA by pulsed-field gel electrophoresis techniques. Nucleic Acids Res (1989) 1.79
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Irreversible block of the mycelial-to-yeast phase transition of Histoplasma capsulatum. Science (1986) 1.78
Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob Agents Chemother (1986) 1.77
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. J Infect Dis (1982) 1.76
Membrane lipid perturbation modifies the set point of the temperature of heat shock response in yeast. Proc Natl Acad Sci U S A (1996) 1.76
Isolation, characterization, and sequencing of Candida albicans repetitive element 2. Gene (1992) 1.73
Variable expression of a yeast-phase-specific gene in Histoplasma capsulatum strains differing in thermotolerance and virulence. Infect Immun (1989) 1.70
Classification of polyene antibiotics according to chemical structure and biological effects. Antimicrob Agents Chemother (1979) 1.69
Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis (1988) 1.68
Cell wall studies of Histoplasma capsulatum. Sabouraudia (1967) 1.68
Possible relationship of morphogenesis in pathogenic fungus, Histoplasma capsulatum, to heat shock response. Nature (1983) 1.67
Antifungal agents: recent developments. Annu Rev Microbiol (1977) 1.66
Correlation between pathogenicity and temperature sensitivity in different strains of Histoplasma capsulatum. J Clin Invest (1986) 1.65
Listeriosis in humans: an evaluation. J Infect Dis (1971) 1.63
Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother (1985) 1.62
Amphotericin B. Old drug, new therapy.?2110. JAMA (1975) 1.61
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects. Antimicrob Agents Chemother (1974) 1.60
Temperature-sensitive variants of Histoplasma capsulatum isolated from patients with acquired immunodeficiency syndrome. J Infect Dis (1990) 1.60
Antimicrobial susceptibility testing of six clinical isolates of Aspergillus. Antimicrob Agents Chemother (1976) 1.59
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Cutaneous mycobacteriosis: analysis of 34 cases with a new classification of the disease. Medicine (Baltimore) (1981) 1.57
Histoplasmosis. An illustrative case with unusual vaginal and joint involvement. Arch Dermatol (1969) 1.55
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia. Cancer Res (1974) 1.52
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
RNA metabolism during morphogenesis in Histoplasma capsulatum. J Gen Microbiol (1974) 1.45
Regulation of dimorphism in the pathogenic fungus Histoplasma capsulatum. Nature (1977) 1.44
A new therapeutic approach to Candida infections. A preliminary report. Arch Intern Med (1972) 1.42